[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552265":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":29,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":29,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":29,"enrollmentInfo":61,"targetDuration":29,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":29,"overallStatus":70,"whyStopped":29,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CHG Combined With Venetoclax and Azacytidine","EXPERIMENTAL","Patients were treated by CHG Combined With Venetoclax and Azacytidine",[13],"Drug: CHG Combined With Venetoclax and Azacytidine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients were treated by CHG Combined With Venetoclax and Azacytidine:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg\u002Fm2 subcutaneous injection qd d1-7; Homoharringtonine 1mg\u002Fm2 iv qd d1-14; Cytarabine 10mg\u002Fm2 subcutaneous injection q12h d1-14; G 250ug\u002Fm2 subcutaneous injection qd d0-14.",[9],[20],"VACHG",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066947192",null,"qlr2007@126.com",[32],{"facility":33,"status":29,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Navy General Hospital","Beijing","Beijing Municipality","100048","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":29,"email":30},"Liren Qian, M.D.","+861066957676",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Liren Qian","Vice Director","100552265","phase-2-chg-combined-with-venetoclax-and-azacytidine-in-newly-diagnosed-aml-100552265",false,"NCT06470841","CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO).\n* The patient should not have received any prior treatment for AML.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","ALL","18 Years",{"count":62,"type":63},85,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.",[69],"Acute Myeloid Leukemia","NOT_YET_RECRUITING","2024-08-21",{"date":73,"type":74},"2024-08-22","ACTUAL",{"date":76,"type":63},"2024-09-20",{"date":78,"type":63},"2028-12",{"name":5,"class":6},1]